Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_2
1
20%
Ph phase_4
1
20%
Ph phase_3
1
20%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_4

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

NCT06697782
terminatedphase_2

Low Dose Aprepitant for Patients Receiving Carboplatin

NCT03237611
completednot_applicable

Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.

NCT04399148
completedphase_1

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

NCT03889366
completedphase_3

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)

NCT01362530

Clinical Trials (5)

Showing 5 of 5 trials
NCT06697782Phase 4

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

Completed
NCT03237611Phase 2

Low Dose Aprepitant for Patients Receiving Carboplatin

Terminated
NCT04399148Not Applicable

Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.

Completed
NCT03889366Phase 1

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

Completed
NCT01362530Phase 3

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5